Market open
X4 Pharmaceuticals/$XFOR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About X4 Pharmaceuticals
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Ticker
$XFOR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
143
Website
XFOR Metrics
BasicAdvanced
$37M
-
-$0.19
0.39
-
Price and volume
Market cap
$37M
Beta
0.39
52-week high
$1.40
52-week low
$0.19
Average daily volume
1.7M
Financial strength
Current ratio
3.412
Quick ratio
3.156
Long term debt to equity
346.901
Total debt to equity
352.549
Interest coverage (TTM)
-16.13%
Management effectiveness
Return on assets (TTM)
-60.18%
Return on equity (TTM)
-102.26%
Valuation
Price to revenue (TTM)
16.678
Price to book
1.64
Price to tangible book (TTM)
-6.97
Price to free cash flow (TTM)
-0.309
Growth
Earnings per share change (TTM)
-67.26%
3-year earnings per share growth (CAGR)
-63.98%
What the Analysts think about XFOR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for X4 Pharmaceuticals stock.
XFOR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
XFOR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
XFOR News
AllArticlesVideos
X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 weeks ago
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·2 weeks ago
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for X4 Pharmaceuticals stock?
X4 Pharmaceuticals (XFOR) has a market cap of $37M as of April 08, 2025.
What is the P/E ratio for X4 Pharmaceuticals stock?
The price to earnings (P/E) ratio for X4 Pharmaceuticals (XFOR) stock is 0 as of April 08, 2025.
Does X4 Pharmaceuticals stock pay dividends?
No, X4 Pharmaceuticals (XFOR) stock does not pay dividends to its shareholders as of April 08, 2025.
When is the next X4 Pharmaceuticals dividend payment date?
X4 Pharmaceuticals (XFOR) stock does not pay dividends to its shareholders.
What is the beta indicator for X4 Pharmaceuticals?
X4 Pharmaceuticals (XFOR) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.